Resistance to Ibritumomab in Lymphoma: 18 (Resistance to Targeted Anti-Cancer Therapeutics, 18) - Image 1

£76.41

Springer Resistance to Ibritumomab in Lymphoma: 18 (Resistance to Targeted Anti-Cancer Therapeutics, 18)

Name: Resistance to Ibritumomab in Lymphoma: 18 (Resistance to Targeted Anti-Cancer Therapeutics, 18)
Brand: Springer
Price: 76.41 GBP
Availability: InStock

Oncology

This is the most expensive it has ever been. Walk away.

£76 today · previous high £76 · all-time low £75

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 72 days · 72 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 72 days • 2 price levels

Days at Price

Current Price

Price Analysis

Most common price: £76 (51 days, 70.8%)

Price range: £75 - £76

Price levels: 2 different prices over 72 days

Description

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Product Specifications

Brand: Springer
Format: hardcover
ASIN: 3319782371
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 07 May 2018
Listed Since: 20 February 2018

Barcode

No barcode data available

Springer Resistance to Ibritumomab in Lymphoma: 18 (Resistance to Targeted Anti-Cancer Therapeutics, 18)

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas: 17 (Resistance to Targeted Anti-Cancer Therapeutics, 17)

Resistance to Ibritumomab in Lymphoma: 18 (Resistance to Targeted Anti-Cancer Therapeutics, 18)

Humana Lymphoma: Methods and Protocols - Methods in Molecular Biology

Aggressive Lymphomas (Hematologic Malignancies)

Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy: 165 (Cancer Treatment and Research, 165)

Radiotherapy for Hodgkin Lymphoma

Hodgkin Lymphoma: A Comprehensive Overview (Hematologic Malignancies)

Immunoconjugate Therapy of Hematologic Malignancies: 68 (Cancer Treatment and Research, 68)

Innovative Leukemia and Lymphoma Therapy: 35 (Basic and Clinical Oncology)

Lymphoma and Leukemia of the Nervous System

Hodgkin Lymphoma: A Comprehensive Overview (Hematologic Malignancies)

Lymphoma: Methods and Protocols: 1956 (Methods in Molecular Biology, 1956)

T-Cell Lymphomas (Contemporary Hematology)

Lymphoma: Diagnosis and Treatment: 43 (Current Clinical Oncology, 43)

PET/CT in Lymphomas: A Case-Based Atlas

Novel Therapeutics for Rare Lymphomas

Cancer Therapy: Monoclonal Antibodies, Lymphokines New Developments in Surgical Oncology and Chemo- and Hormonal Therapy

Current Immunotherapeutic Strategies in Cancer: 214 (Recent Results in Cancer Research, 214)

Gene and Cellular Immunotherapy for Cancer (Cancer Drug Discovery and Development)

Blut und Blutkrankheiten: Fünfte Völlig Neu Bearbeitete und Erweiterte Auflage: 2 / 7 (Handbuch der inneren Medizin, 2 / 7)

Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America: Volume 34-5 (The Clinics: Internal Medicine, Volume 34-5)